Cannabis Trial South Africa
Take part in our cannabis trial South Africa.
Should you wish to apply kindly fill out the form below.
All data and personal information will be kept strictly confidential and will not be sold, reused, or otherwise disclosed.
Application is free.
Should your application be approved there is a monthly fee for the duration of the study.
This fee provides for:
- 15 grams lab tested cannabis (15g in 0.5g doses) per month OR 1 month’s supply of cannabis oil
- Monthly blood test
- Access to a qualified Doctor
This observational clinical cannabis study is open to South Africans who qualify.
Are you currently using cannabis for medicinal use? Have you been concerned about the quality of the product you are using? Do you wish to explore the option of medicinal marijuana as a treatment option?
Medical Cannabis SA, together with Biodata Research, will be running an observational cannabis study in order to provide participants with lab tested cannabis and/or cannabis oil.
These South African participants will take part in the cannabis trial over the course of a few months and the results recorded.
Clinical observational cannabis trials are one of the access pathways for medical cannabis in South Africa.
Below, you’ll find everything you need to know about how this observational cannabis trial will work, why it’s important and how you can get involved!
What is the purpose of conducting an observational cannabis trial in South Africa?
It can be difficult to locate information about the safety and therapeutic value of cannabis. An unfortunate result of the prohibition of cannabis has been limited clinical research to investigate the safety and efficacy of cannabis to control symptoms of serious and chronic illness. Many scientists have noted research is “hindered by a complicated approval process, limited availability of research grade cannabis and the debate over patient access.
Nonetheless, the documented use of cannabis as a safe and effective therapeutic botanical dates to 2700 BC. Between 1840 and 1900, European and American journals of medicine published more than 100 articles on the therapeutic use of cannabis. In fact, cannabis was part of the American pharmacopoeia until 1942, and is currently available by prescription in Canada, the Netherlands, Israel, and Germany.
Modern research suggests that cannabis is a valuable aid in the treatment of a wide range of clinical applications. These include pain relief — particularly neuropathic pain — nausea, spasticity, glaucoma, and movement disorders. Cannabis is also a powerful appetite stimulant, specifically for patients suffering from HIV, the AIDS wasting syndrome, or dementia. Emerging research suggests that cannabinoids and terpenes found in cannabis work together synergistically to help protect the body against some types of malignant tumors.
Observational cannabis trials in South Africa such as this are crucial for the future of the medical cannabis space.
While we need more large randomized controlled trials, they will be slow and few and far between.
Until then this cannabis trial will offer doctors, researchers and SAHPRA data to assist with understanding patient use of cannabis for medicinal use in South Africa.
What criteria is required to take part in this cannabis trial?
- Patient, or legal representative, willing and able to give informed consent for participation in the study.
- Male or Female, aged 21 years or above.
- Diagnosed with chronic refractory pain due to Multiple Sclerosis or other defects of neurological function.
- Willing to abstain from any OTHER use of cannabis during the study.
- Able (in the investigator’s opinion) and willing to comply with all study requirements.
- Willing for his or her name to be notified to SAHPRA for participation in this study.
- Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study.
- History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- Severe cardiovascular disorder, such as ischemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure.
- Female patients who were pregnant, lactating or planning pregnancy during the course of the study.
- Significant renal or hepatic impairment.
- Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medications.
- Known or suspected of having adverse reaction to cannabinoids.